-
-
Toggle navigation
Impact Factor 3.845 | CiteScore 3.92
More on impact ›
in Pharmacology |
|
Submit your manuscript
Scope
ELSI in Science and Genetics publishes scholarship that counteracts or anticipates the emerging ethical, legal, and social implications of rapid technological advances in the biomedical sciences.
Read More
Scope
Unappreciated ethical, legal, and social implications (ELSI) have resulted from recent, often permissionless, rapid and expansive advances in the biological sciences. Whereas in the past many issues were tackled post factum, ELSI, which was initially spurred and funded by the Human Genome Project, continues to expand in its reach. ELSI efforts often track US-government–funded big projects. Thus, whereas ELSI started out as simply associated with human genetics, with government efforts in neuroscience, ELSI has expanded into the growing area of neuroethics. And now, with the Obama Administration’s Precision Medicine Initiative, ELSI aspects are particularly relevant in the area of pharmacological innovation where issues such as privacy, regulation, intellectual property, open science, medicrime, and access to medicines take on real relevance. Current ELSI efforts aim to deal with problems as they arise, and even to anticipate, and provide guidance for, future developments. Importantly, in anticipating future concerns resulting from research, many ELSI researchers aim to preempt innovation hampering regulation that is anyway often too little, too late. Mirroring the increasing trend towards multidisciplinary work in the life sciences and beyond, this section unabashedly seeks contributions from a wide variety of disciplines and practices in an effort to develop a broad-based multidisciplinary understanding of the ever-changing ethical, legal, and social issues in the biological sciences, and to stimulate academic and public discourse in this area. We invite original contributions within ELSI from scientists, lawyers, philosophers, sociologists, practitioners, policy makers, regulators, journalists, or a combination thereof. ELSI issues relating to genetics, genomics, synthetic biology, reproductive technologies, pharmacology health and clinical issues, government regulation, privacy, intellectual property, constitutional law, morality, society, and beyond are welcome. We hope that this cross-disciplinary forum will provide grounds for fertile discussion and debate in this important and evolving field. Given the expected broad base of authors, some aspects of publication will necessarily be somewhat flexible to accommodate the vastly different disciplines that contribute to ELSI research.Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS)
PMCID: all published articles receive a PMCID
ELSI in Science and Genetics welcomes submissions of the following article types: Brief Research Report, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section ELSI in Science and Genetics, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section ELSI in Science and Genetics will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Pharmacology, Genetics and Sociology.
Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
There are no results to display.
Click on any of the keywords to find further editors related to it.
- Article(s) found
- Latest
- Most viewed
This section has no articles.
There are no articles to display. Please try changing the filters.
- Research Topic(s) found
- Latest
- Most viewed
Contact Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact pharmacology.editorial.office@frontiersin.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact pharmacology@frontiersin.org
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
For technical issues, please visit our Frontiers Help Center, or contact our IT HelpDesk team at support@frontiersin.org